A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1192 participants.
Also called NCT07842185
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 1,192 participants
- Registry
-
NCT07842185
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07842185. Randomized; double masking; primary purpose treatment. Start 2026-12-19 (anticipated); primary completion 2030-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
- Acronym
- INSTANT-2
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Tirofiban Injection
- Intervention (Drug)
- Tirofiban Injection
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Collaborator
- The Affiliated Ganzhou Hospital of Nanchang University
Record details
- Record id
cardio:ct-nct07842185- Content hash
c593732ccf767351335983ffb001f23b7a9d730362cea9d7a357539196833d1d